Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
about
Case-based study: from prediabetes to complications--opportunities for preventionPioglitazone for people with impaired glucose tolerance or impaired fasting blood glucosePioglitazone for people with impaired glucose tolerance or impaired fasting blood glucoseAbscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gammaCardiovascular safety of anti-diabetic drugsRegulation of brown adipose tissue recruitment, metabolism and thermogenic function by peroxisome proliferator-activated receptor γDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesPPARs: Protectors or Opponents of Myocardial Function?Use of metformin in diseases of agingAdvancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesThiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium RetentionPPARgamma-Dependent Control of Renin Expression: Molecular Mechanisms and Pathophysiological RelevanceUpdates on the management of diabetes in dialysis patientsNutritional protective mechanisms against gut inflammationUpdate on the treatment of type 2 diabetes mellitusThe CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the HeartDietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γPeroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusionEchocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitusDiabetic nephropathy - Epidemiology in Asia and the current state of treatmentOphiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse modelThe current role of thiazolidinediones in diabetes management.The management of type 2 diabetic patients with hypoglycaemic agentsIncreased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retentionVirtual Screening as a Technique for PPAR Modulator Discovery.Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseIs there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesMinireview: Challenges and opportunities in development of PPAR agonistsConjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma.Oral antihyperglycemic therapy for type 2 diabetes mellitus.Pear pomace ethanol extract improves insulin resistance through enhancement of insulin signaling pathway without lipid accumulation.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retentionAbscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis.Heart failure in the diabetic population - pathophysiology, diagnosis and management.PPARs in the Renal Regulation of Systemic Blood Pressure
P2860
Q21144738-62B6E494-24DF-4A1F-A272-39034C0342B9Q24195168-CA18734C-2AFD-4D8B-B0A0-745DD0D549A0Q24202245-E992EA65-FFF0-478E-8024-EF12256CD52FQ24634256-72D6C06D-88F0-40A3-A001-33E3E1817ADFQ26741082-D5536627-766D-49AD-8BFC-7B88458C029EQ26745781-6403B0EA-C380-420D-8EBD-DE4E3D177868Q26749281-B2E12530-1A7D-4488-8E68-9CFFB97E3A5DQ26771753-5832D17A-0E8D-4366-8771-70233EC3D17BQ26828760-E0088F19-3940-4BDD-8532-948DA6FC3D78Q26829985-63845AD8-AB57-4309-8289-C331531E2B54Q26851905-92337274-6939-4973-B79D-1B7E95FE3422Q27009036-75134CFF-6D47-4792-8916-E03519E8EC4CQ27024782-EE2BF736-9D58-48E7-9858-CD126D65E009Q27028202-1F1EC5FA-8F85-495B-93B6-46EB99D4C873Q28073342-77C7C2A6-2D62-4264-8D62-60239CCE837FQ28079006-B6C57861-0733-49BC-B508-FDDED97771ABQ28476741-2844D438-175E-463D-952B-77D5B8A806A3Q28478187-164317C1-4218-4E11-A355-4CA715E57D4DQ28480527-14A9C5CF-AC19-4718-8C52-09C0D55C30ADQ28742785-CD66CD74-1DEE-44E5-A03D-C561B879FDC8Q28829254-BA11CB73-2734-45C6-ABA6-DD67B65B9832Q30250347-DC0380A4-A40B-4508-ABC3-7C2596A39785Q30417363-12A94A73-CC06-49F6-A12A-DE19BDAE8EEFQ30433046-AA9245C3-A493-422E-86E3-44CAD7D38F19Q30717371-8C5C9089-5D91-4465-848F-2717BBD7B9A2Q33502225-BAF1D457-777E-4917-B415-BA7E8FA4087CQ33527739-348E5A1A-ED1D-4D32-944F-0F44B2D3F093Q33561396-B7467AC1-A4E8-45B7-B0C7-175B50BD1855Q33590792-FF9AFB84-B3A5-4F3E-B29C-AA33E420D16CQ33607697-2DF34B03-FF84-41BE-8866-86E2AC155F27Q33610682-AE3B34D6-CEA3-4C63-B2FD-F525788C35EDQ33631921-C8DBEE09-FCE7-43B8-86F2-B5A5CBCBAF9CQ33652897-BAB96C3C-1130-47A3-B784-68E4960798A3Q33713451-FB193012-F6AB-4596-AA60-E91F2CEFD672Q33740292-D6CB36AB-6A8A-4323-BFD3-5068DE641A7BQ33815573-F0897DD9-5BC2-413F-8A48-025BF80F5529Q33878917-BF21818C-B11E-4EB2-967D-2198CCA81F99Q33925358-07AF953B-0D9A-4660-A509-7094A79FFEF9Q33935375-8F6DDC33-10D9-4A91-A373-5B1C40F5FAF7Q33960908-1626C692-0DC3-404F-ABEA-465EAC7140A1
P2860
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@ast
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@en
type
label
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@ast
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@en
prefLabel
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@ast
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@en
P2093
P50
P1433
P1476
Thiazolidinedione use, fluid r ...... Association. October 7, 2003.
@en
P2093
Daniel Porte
David Bell
Edward S Horton
Lawrence H Young
Martin Le Winter
Richard Kahn
Richard W Nesto
Robert O Bonow
Scott M Grundy
Vivian Fonseca
P304
P356
10.1161/01.CIR.0000103683.99399.7E
P407
P577
2003-12-01T00:00:00Z